Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Allergic Drug Reactions

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...

Pharmacovigilance

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

Local Anesthetics: Adverse Effects

Local Anesthetics: Adverse Effects

While local anesthetics are generally safe and well-tolerated, they can occasionally cause adverse effects that vary in severity. Local anesthetics can induce toxicity at two distinct levels. They can either produce local effects through direct contact with the neural elements or be absorbed into the bloodstream from the injection site, leading to systemic effects.
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Use of Dupilumab to Manage Antibody-Drug Conjugate-Induced Cutaneous Toxicities.

JAMA dermatology·2025

Same author

A Rare Case of Primary Cutaneous Gamma-Delta T-cell Lymphoma with Aberrant B-cell Marker Expression.

The American Journal of dermatopathology·2023

Same author

Lower extremity nodules in an immunocompetent woman.

JAAD case reports·2021

Same author

Employing immunohistochemical staining to labial minor salivary gland biopsies from patients with Sjogren's syndrome increases diagnostic certainty.

Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·2020

Same author

Proliferating pilomatricoma in a 9-year-old girl.

Pediatric dermatology·2020

Same author

Angiolymphoid hyperplasia with eosinophilia treated with Mohs micrographic surgery.

Dermatology online journal·2020

Search research articles

Related Experiment Video

Updated: Sep 10, 2025

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis

Published on: March 14, 2025

A Unique Dermatologic Adverse Event from Enfortumab Vedotin.

Megan Bielawa¹, Apoorva Trivedi²

¹Memorial Sloan Kettering Dermatology Service, 800 Veterans Memorial Highway 2 Floor, Hauppauge NY 11788.

Journal of Dermatology for Physician Assistants : Official Journal of the Society of Dermatology Physician Assistants

|August 25, 2025

Summary

Enfortumab vedotin (EV) can cause rare but significant skin reactions like blistering. Early recognition and management of these dermatologic toxicities are vital for continuing cancer treatment.

Keywords:

bullous dermatitis cutaneous toxicities enfortumab vedotin immunotherapy urothelial cancer

More Related Videos

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice

Published on: January 19, 2018

Related Experiment Videos

Last Updated: Sep 10, 2025

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis

Published on: March 14, 2025

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice

Published on: January 19, 2018

Area of Science:

Oncology
Dermatology

Background:

Enfortumab vedotin (EV) is a chemotherapy for metastatic urothelial cancer.
Rashes are common EV side effects, but literature on bullous dermatoses is limited.

Purpose of the Study:

To report a unique case of bullous dermatosis associated with EV therapy.
To review diagnostic workup and management strategies for EV-induced skin toxicities.

Main Methods:

Case report detailing a patient's experience with EV.
Review of diagnostic procedures and treatment interventions for bullous dermatosis.

Main Results:

A unique bullous dermatosis presentation in a patient receiving EV was observed.
The case highlights the importance of recognizing and managing EV-related cutaneous adverse events.

Conclusions:

Dermatologic toxicities, including bullous reactions, can occur with enfortumab vedotin.
Prompt identification and management of these adverse events are crucial for patient care and treatment adherence.